EGF receptor as a therapeutic target.
EGFR and Her-2 are overexpressed in lung cancers and have, therefore, been chosen as preferred targets for novel therapies. Recent results on Iressa trials show only a moderate response to the agent, even in cases where it is documented that EGFR is over-expressed. These findings prompted us to re-visit the oncogenic pathways, which play a role in lung cancers, with special emphasis on the way EGFR/Her-2 signaling cooperates with other signaling pathways.
Levitzki
Alexander
A
Unit of Cellular Signaling, Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, 91904, Israel. levitzki@vms.huji.ac.il
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002471:Cell Transformation, Neoplastic; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D066246:ErbB Receptors / Q000502:physiology*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology*; D011505:Protein-Tyrosine Kinases / Q000494:pharmacology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000502:physiology*; D015398:Signal Transduction
D000911:Antibodies, Monoclonal; D004791:Enzyme Inhibitors; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D018719:Erb-b2 Receptor Tyrosine Kinases